Daiichi Sankyo

In recent years, the rapid growth of China's economy has attracted worldwide attention, and the level of medical care has been continuously improving. China's pharmaceutical market has surpassed Japan to become the second largest in the world after the United States, and it continues to grow. In the recently released Chinese government report, the "Healthy China Strategy" was clearly proposed, and relevant departments are continuously deepening medical and health reforms and promoting the healthy growth of the pharmaceutical market.

The unique charm and development prospects of the Chinese market have attracted numerous foreign-funded pharmaceutical enterprises to flock in. As an original research-based multinational group with a history of over 120 years, *Sankyo began introducing many excellent original research products to China as early as the 1980s and has continuously expanded its business in China.

As one of the global pharmaceutical companies, *Sankyo has successfully established business institutions in China, including R&D, production, and sales.

*Sankyo's excellent product quality is continuously being recognized and accepted by the industry, patients, and other users. These achievements are all attributed to the innovative and transformative work style that *Sankyo people have always adhered to. As the global pharmaceutical war intensifies, *Sankyo China continues to break through and transform, making our journey in China particularly splendid.

The market environment is changing rapidly, and national policies are constantly being adjusted. Both foreign and local enterprises are facing opportunities and challenges in multiple aspects such as production and R&D, commercial operations, marketing, and market access. In this environment where opportunities and challenges coexist, we actively think and continuously adjust our development strategies. Based on the characteristics of the environment and policies, we have carried out diversified cooperation models, effectively integrated various resources, and while providing excellent pharmaceuticals, we continuously provide high value-added products. We actively transform towards the oncology and special disease fields, promote the launch of new drugs, in order to achieve the goal of "contributing to improving the quality of life for people around the world."

In the future, we will continue to keenly perceive changes in the environment, establish correct development strategies, build an excellent staff team, provide more professional academic services, and form a competitive product portfolio. This is our unwavering commitment to the Chinese market, and we firmly believe in *Sankyo's success in the Chinese market!

*Sankyo China has always adhered to the core values of "Innovation", "Integrity", and "Accountability", conducting business with the highest moral standards, continuously pursuing innovation, providing high-quality products, and practicing the corporate philosophy of "continuously launching innovative drugs, providing pharmaceuticals that meet various medical needs, and contributing to the health and well-being of people globally."

We will grow together with the Chinese pharmaceutical market, safeguard the health of the Chinese people, and create new value!